• Subscribe
  • Log In
  • Home
  • Daily Diary
  • Asset Class
    • U.S. Equity
    • Fixed Income
    • Global Equity
    • Commodities
    • Currencies
  • Sector
    • Basic Materials
    • Consumer Discretionary
    • Consumer Staples
    • Energy
    • Financial Services
    • Healthcare
    • Industrials
    • Real Estate
    • Technology
    • Telecom Services
    • Transportation
    • Utilities
  • Latest
    • Articles
    • Video
    • Columnist Conversations
    • Best Ideas
    • Stock of the Day
  • Street Notes
  • Authors
    • Doug Kass
    • Bruce Kamich
    • Jim Cramer
    • Jim "Rev Shark" DePorre
    • Helene Meisler
    • Jonathan Heller
    • - See All -
  • Options
  • RMPIA
  • Switch Product
    • Action Alerts PLUS
    • Quant Ratings
    • Real Money
    • Real Money Pro
    • Retirement
    • Stocks Under $10
    • TheStreet
    • Top Stocks
    • Trifecta Stocks
  1. Home
  2. / Investing

Jim Cramer: My Take on These Companies Where Lawsuits Are Front and Center

These are currently situations where companies are facing serious lawsuits.
By JIM CRAMER
Dec 19, 2018 | 02:11 PM EST
Stocks quotes in this article: QCOM, AAPL, JNJ, FB, GS, AGN

There's earnings. There's forecasts. And then there are lawsuits. The first two are pretty easy to figure out what will happen.

The third is a real wild card. Right now there are four situations where lawsuits are front and center: Qualcomm (QCOM) versus Apple (AAPL) ; Johnson & Johnson (JNJ) versus myriad users of talc who have contracted cancer; the District of Columbia's lawsuit just filed against Facebook (FB) ; and the Malaysian government's prosecution of Goldman Sachs (GS) for fraud. At the same time the market's reacting today, to potential lawsuits that could be filed against Allergan (AGN) for the sale of certain breast implants that could cause a rare form of cancer, a concern that caused sales to be suspended throughout Europe.

Let's break them down judging the severity of each to the stock price of the companies involved.

Qualcomm vs. Apple

I want to start with Qualcomm's litigation with Apple because it had, I believe, a much bigger impact on Apple's stock than anything other than the possibility of a very big fall off in Apple iPhone sales. That's because Qualcomm's got a judge in an obscure province in China who has ruled that certain models of Apple's iPhone can't be sold. Why does this matter? Because if you look at the Chinese org chart, so to speak, you will realize that every court is controlled by the Communist Party. As much as I think that Apple's a good citizen in China, this lawsuit is, in many ways, more important than the federal court suit that is supposed to be tried early next year in San Diego. Apple doesn't want to settle, has no plans to settle and so the potential bad news hangs out there. We know China's worth more to the stock even then it has already fallen. Put it on the watch list and understand that it can be undone if the two parties do settle and Qualcomm wants a settlement.

Johnson & Johnson

Next, Johnson & Johnson is being sued by about 12,000 women who claim to have gotten cancer from the asbestos in talc. The hot button here: two big articles that directly accused JNJ of knowingly selling a product for multiple years that contained asbestos which causes cancer. Alex Gorsky CEO of JNJ, came on Mad Money and denied these charges vociferously. Meanwhile today the court that ruled against JNJ for a $4.69 billion judgment on behalf of a group of women in Missouri, rejected a rehearing by JNJ. It seemed like a big deal but you have to expect the same judge to not change his mind. This one will now go to an appellate court. Meanwhile, come next summer, a New Jersey federal court, reviewing multi-district cases of about 8,000 women, will consider the science and the facts on the way to making a ruling that could stick and hurt JNJ if the drug company loses.

I know JNJ doesn't want to settle. I know it thinks it can overturn the Missouri verdict on appeal. My take? The stock has already collapsed, losing more than $50 billion, which even the lead plaintiff's lawyer thought was in excess of what could happen. This one seems like a buy, but wait a week, see if the story dies down, especially now that some are speculating that Gorsky and other execs sold stock ahead of the news stories. I think that's unfair. But it is out there.

Goldman Sachs

The lawsuit by the Malaysian government against Goldman Sachs for its role in the 1MBD scandal has weighed mightily on the scandal as has the investigation by the U.S. government. My take? Goldman, I believe, will have to settle and agree to cough up money and change its compliance policies, which I regard as already strict. I think it ends there, but it will be an issue for months, not weeks. Not for the faint of heart: but the stock is selling for less than if they closed the doors and distributed the cash.

Facebook

Facebook? All I can say is "what took so long?" This one is a District of Columbia Attorney General bringing suit for violations of the District of Columbia's Consumer Protection Procedures Act. I predict many more of these and great reputational risk. But I still doubt that the advertisers will stay away. Nevertheless, the bunker mentality, the refusal to appoint an outside law firm of some renown to get to the bottom of this means there will be many more of these suits. Not good, but ultimately more settlements and no more.

Allergan

Finally, many are panicking that Allergan has big exposure for the rare breast cancer issue. There's good news for Allergan: the danger was well-known. The bad news: you are going to read many articles about both the sadness and the liability including, most likely, lawsuits. Because Allergan's balance is less than pristine there will be plenty of worry here and, yes, once again, settlements.

Every one of these is a serious taint. The stocks, though, have been hammered already. It's more headline risk going forward. All I ask is for you to ask yourself if you can handle those headlines. These stock will ultimately sink or swim on their fundamentals, I just don't know how long "ultimately" will take.

Get an email alert each time I write an article for Real Money. Click the "+Follow" next to my byline to this article.

Jim Cramer and the AAP team hold positions in Apple, Johnson & Johnson, Facebook and Goldman Sachs for their Action Alerts PLUS Charitable Trust Portfolio . Want to be alerted before Cramer buys or sells AAPL, JNJ, FB or GS? Learn more now.

TAGS: Investing

More from Investing

The Psilocybin Patent Race Is On

Debra Borchardt
Mar 6, 2021 12:30 PM EST

It feels like these companies are casting a wide net, but it makes sense to file at the beginning of this mushroom mania.

The Challenge of Short Selling

James "Rev Shark" DePorre
Mar 6, 2021 10:00 AM EST

Short selling is a powerful tool, but it is not just the inverse of going long and requires a very different mindset to do it effectively.

Kass: There Are Many Reasons to Be a Bear

Doug Kass
Mar 6, 2021 8:15 AM EST

I believe the markets are headed lower - probably not in a straight line or as steep as the last few days, but in a saw tooth fashion lower.

Bounce Takes Some of the Sting Out of a Painful Week

James "Rev Shark" DePorre
Mar 5, 2021 4:51 PM EST

It is premature to declare that the worst is over, but the intensity of the selling will go a long way toward helping a bottom to form.

The Selloff in Twilio Could Extend Deeper Into March

Bruce Kamich
Mar 5, 2021 2:30 PM EST

TWLO could bounce in the short-run but avoid the long side for now.

Real Money's message boards are strictly for the open exchange of investment ideas among registered users. Any discussions or subjects off that topic or that do not promote this goal will be removed at the discretion of the site's moderators. Abusive, insensitive or threatening comments will not be tolerated and will be deleted. Thank you for your cooperation. If you have questions, please contact us here.

Email

CANCEL
SUBMIT

Email sent

Thank you, your email to has been sent successfully.

DONE

Oops!

We're sorry. There was a problem trying to send your email to .
Please contact customer support to let us know.

DONE

Please Join or Log In to Email Our Authors.

Email Real Money's Wall Street Pros for further analysis and insight

Already a Subscriber? Login

Columnist Conversation

  • 11:38 AM EST GARY BERMAN

    The INDU and DIA

    FIBOCALL: The INDU index and the DIA The INDU ...
  • 10:44 AM EST JAMES "REV SHARK" DEPORRE

    This Weekend on Real Money

    "The Challenge of Short-Selling"
  • 08:40 AM EST PAUL PRICE

    Recent Pick SpartanNash (SPTN) Raised Its Quarterly Payout by 3.9%

  • See More

COLUMNIST TWEETS

  • A Twitter List by realmoney
About Privacy Terms of Use

© 1996-2021 TheStreet, Inc., 225 Liberty Street, 27th Floor, New York, NY 10281

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.

Compare Brokers

Please Join or Log In to manage and receive alerts.

Follow Real Money's Wall Street Pros to receive real-time investing alerts

Already a Subscriber? Login